Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.

Cohen EEW, Pishvaian MJ, Shepard DR, Wang D, Weiss J, Johnson ML, Chung CH, Chen Y, Huang B, Davis CB, Toffalorio F, Thall A, Powell SF.

J Immunother Cancer. 2019 Dec 4;7(1):342. doi: 10.1186/s40425-019-0815-6.

2.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.

Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.

3.

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.

Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR.

Oncologist. 2019 Sep;24(9):1151-e817. doi: 10.1634/theoncologist.2018-0749. Epub 2019 Jun 6.

4.

Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.

Saif MW, Rosen L, Rudek MA, Sun W, Shepard DR, Becerra C, Yamashita F, Bebeau P, Winkler R.

Br J Clin Pharmacol. 2019 Jun;85(6):1239-1246. doi: 10.1111/bcp.13856. Epub 2019 Mar 28.

PMID:
30628113
5.

Adult Primary Bone Sarcoma and Time to Treatment Initiation: An Analysis of the National Cancer Database.

Lawrenz JM, Curtis GL, Styron JF, George J, Anderson PM, Zahler S, Shepard DR, Rubin BP, Nystrom LM, Mesko NW.

Sarcoma. 2018 Nov 11;2018:1728302. doi: 10.1155/2018/1728302. eCollection 2018.

6.

Adult soft tissue sarcoma and time to treatment initiation: An analysis of the National Cancer Database.

Curtis GL, Lawrenz JM, George J, Styron JF, Scott J, Shah C, Shepard DR, Rubin B, Nystrom LM, Mesko NW.

J Surg Oncol. 2018 Jun;117(8):1776-1785. doi: 10.1002/jso.25095. Epub 2018 Jun 27.

PMID:
29949654
7.

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.

Gupta N, Zhang S, Pusalkar S, Plesescu M, Chowdhury S, Hanley MJ, Wang B, Xia C, Zhang X, Venkatakrishnan K, Shepard DR.

Invest New Drugs. 2018 Jun;36(3):407-415. doi: 10.1007/s10637-017-0509-1. Epub 2017 Sep 21.

8.

Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.

Wang D, Braiteh F, Lee JJ, Denlinger CS, Shepard DR, Chaudhary A, Lin Y, Gao L, Asakiewicz C, Nasroulah F, LoRusso P.

Cancer Chemother Pharmacol. 2016 Oct;78(4):727-33. doi: 10.1007/s00280-016-3125-4. Epub 2016 Aug 9.

PMID:
27507037
9.

Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors.

Chow LQ, Smith DC, Tan AR, Denlinger CS, Wang D, Shepard DR, Chaudhary A, Lin Y, Gao L.

Cancer Chemother Pharmacol. 2016 Aug;78(2):433-41. doi: 10.1007/s00280-016-3098-3. Epub 2016 Jul 5.

10.

Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors.

Smith DC, Powderly J, Lee JJ, Shepard DR, Wallin J, Chaudhary A, Chao GY, Ng WT, Mitchell MI, Grau G, Kurek R, LoRusso P.

Cancer Chemother Pharmacol. 2016 Aug;78(2):271-80. doi: 10.1007/s00280-016-3074-y. Epub 2016 Jun 16.

PMID:
27312733
11.

A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.

Shepard DR, Cooney MM, Elson P, Bukowski RM, Dreicer R, Rini BI, Garcia JA.

Invest New Drugs. 2012 Feb;30(1):364-7. doi: 10.1007/s10637-010-9516-1. Epub 2010 Aug 14.

PMID:
20711630
12.

Zibotentan for the treatment of castrate-resistant prostate cancer.

Shepard DR, Dreicer R.

Expert Opin Investig Drugs. 2010 Jul;19(7):899-908. doi: 10.1517/13543784.2010.491822. Review.

PMID:
20497097
13.

Editorial comment.

Shepard DR.

Urology. 2010 May;75(5):1137. doi: 10.1016/j.urology.2009.11.061. No abstract available.

PMID:
20451735
14.

Innovations in the systemic therapy of prostate cancer.

Shepard DR, Raghavan D.

Nat Rev Clin Oncol. 2010 Jan;7(1):13-21. doi: 10.1038/nrclinonc.2009.187. Epub 2009 Dec 8. Review.

PMID:
19997075
15.

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.

Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms SA, Vogelbaum MA, Weil RJ, Elson P, Barnett GH.

J Neurooncol. 2010 May;98(1):93-9. doi: 10.1007/s11060-009-0067-2. Epub 2009 Dec 4.

PMID:
19960228
16.

Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.

Shepard DR, Garcia JA.

Expert Rev Anticancer Ther. 2009 Jun;9(6):795-805. doi: 10.1586/era.09.29. Review.

PMID:
19496716
17.

Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.

Shepard DR, Dreicer R, Garcia J, Elson P, Magi-Galluzzi C, Raghavan D, Stephenson AJ, Klein EA.

J Urol. 2009 Apr;181(4):1672-7; discussion 1677. doi: 10.1016/j.juro.2008.11.121. Epub 2009 Feb 23.

PMID:
19230915
18.

Gender, hyperlipidemia, and coronary artery disease.

Shepard DR, Jneid H, Thacker HL.

Compr Ther. 2003 Spring;29(1):7-17. Review.

PMID:
12701338
19.

Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.

Shepard DR, Mani S, Kastrissios H, Learned-Coughlin S, Smith D, Ertel P, Magnum S, Janisch L, Fleming GF, Schilsky RL, Ratain MJ.

Cancer Chemother Pharmacol. 2002 May;49(5):398-402. Epub 2002 Feb 23.

PMID:
11976834
20.

Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.

Iyer L, Ramírez J, Shepard DR, Bingham CM, Hossfeld DK, Ratain MJ, Mayer U.

Cancer Chemother Pharmacol. 2002 Apr;49(4):336-41. Epub 2002 Feb 1.

PMID:
11914914
21.

Gallium nitrate suppresses the production of nitric oxide and liver damage in a murine model of LPS-induced septic shock.

Krecic-Shepard ME, Shepard DR, Mullet D, Apseloff G, Weisbrode SE, Gerber N.

Life Sci. 1999;65(13):1359-71.

PMID:
10503955
22.

The effects of gallium nitrate on osteopenia induced by ovariectomy and a low-calcium diet in rats.

Stern LS, Matkovic V, Weisbrode SE, Apseloff G, Shepard DR, Mays DC, Gerber N.

Bone Miner. 1994 Apr;25(1):59-69.

PMID:
8061552
23.

Aminohydroxybutane bisphosphonate and clenbuterol prevent bone changes and retard muscle atrophy respectively in tail-suspended rats.

Apseloff G, Girten B, Walker M, Shepard DR, Krecic ME, Stern LS, Gerber N.

J Pharmacol Exp Ther. 1993 Mar;264(3):1071-8.

PMID:
8450451
24.

Lack of effect of gallium nitrate on bone density in a rat model of simulated microgravity.

Apseloff G, Girten B, Gerber N, Shepard DR, Matkovic V.

Aviat Space Environ Med. 1992 Jan;63(1):27-31.

PMID:
1550530
25.

Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans.

Apseloff G, Shepard DR, Chambers MA, Nawoot S, Mays DC, Gerber N.

Drug Metab Dispos. 1990 May-Jun;18(3):298-303.

PMID:
1974189
26.

Use of gallium to treat Paget's disease of bone: a pilot study.

Matkovic V, Apseloff G, Shepard DR, Gerber N.

Lancet. 1990 Jan 13;335(8681):72-5.

PMID:
1967419

Supplemental Content

Loading ...
Support Center